HC Wainwright Issues Optimistic Forecast for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at HC Wainwright raised their Q1 2026 earnings estimates for shares of Voyager Therapeutics in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.28) per share for the quarter, up from their prior estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at ($0.91) EPS.

Separately, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Voyager Therapeutics has an average rating of “Hold” and a consensus price target of $16.50.

Voyager Therapeutics Price Performance

VYGR opened at $3.74 on Thursday. The business has a 50 day moving average price of $3.91 and a two-hundred day moving average price of $4.19. The company has a market capitalization of $222.90 million, a price-to-earnings ratio of -1.84 and a beta of 1.32. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. The business had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its stake in Voyager Therapeutics by 42,410.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after purchasing an additional 15,692 shares during the period. Invesco Ltd. lifted its holdings in shares of Voyager Therapeutics by 28.2% in the fourth quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock valued at $456,000 after purchasing an additional 25,522 shares in the last quarter. Sphera Funds Management LTD. boosted its position in shares of Voyager Therapeutics by 70.1% in the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock worth $1,335,000 after buying an additional 140,000 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Voyager Therapeutics in the fourth quarter worth $120,000. Finally, Opaleye Management Inc. purchased a new position in shares of Voyager Therapeutics during the fourth quarter valued at $4,704,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total value of $53,806.63. Following the completion of the transaction, the chief executive officer directly owned 484,060 shares in the company, valued at $1,834,587.40. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 49,783 shares of company stock valued at $188,694 in the last ninety days. Company insiders own 6.39% of the company’s stock.

Key Headlines Impacting Voyager Therapeutics

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised several near‑term 2026 quarterly and full‑year EPS forecasts (Q1–Q4 2026 and FY2026 showed modest improvements), signaling improved near‑term expectations and keeping a $25 price target well above the current share price. Article Title
• Neutral Sentiment: Media coverage summarized analyst commentary on healthcare names including Voyager; these pieces provide background and analyst viewpoints but contain no new company‑specific data beyond the HC Wainwright notes. Article Title
• Negative Sentiment: Alongside the near‑term bumps, HC Wainwright trimmed several longer‑term EPS projections for FY2027–FY2030 (notably FY2027–FY2029 and FY2030 adjustments), lowering the multi‑year profitability outlook — a bearish factor for valuation given Voyager’s loss profile and need for clinical/operational execution to realize upside. Article Title

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.